Structured evidence table for Inulin Gut Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Inulin Gut Randomized Trial | Our previous work demonstrated that patients with OLP exhibit reduced gut microbial diversity and a marked depletion of butyrate‑producing bacteria compared with healthy individuals []. | 2 | Nambu Koki (2026) | Study protocol: Effect of inulin supplementation on gut microbiota in patients with oral lichen planus — A double-blind, randomised, placebo-controlled parallel-group trial |
| Inulin Gut Randomized Trial | Given that OLP is characterised by dysbiosis with reduced butyrate‑producing bacteria, inulin supplementation may help restore microbial balance and modulate immune responses. | 2 | Nambu Koki (2026) | Study protocol: Effect of inulin supplementation on gut microbiota in patients with oral lichen planus — A double-blind, randomised, placebo-controlled parallel-group trial |
| Inulin Gut Randomized Trial | The findings of this trial are expected to provide foundational evidence for prebiotic supplementation as an adjunctive microbiota-directed strategy in OLP. | 2 | Nambu Koki (2026) | Study protocol: Effect of inulin supplementation on gut microbiota in patients with oral lichen planus — A double-blind, randomised, placebo-controlled parallel-group trial |
| Inulin Gut Randomized Trial | 1 2 3 Oral lichen planus (OLP) is a chronic inflammatory disease of the oral mucosa characterised by T-cell–mediated immune dysregulation [,]. | 2 | Nambu Koki (2026) | Study protocol: Effect of inulin supplementation on gut microbiota in patients with oral lichen planus — A double-blind, randomised, placebo-controlled parallel-group trial |
| Inulin Gut Randomized Trial | Next, we integrate these fermentation and microbial-utilization features to explain the rationale for co-administration with long-chain inulin and review the available preclinical evidence. | 3 | Fujii Tadashi (2026) | 1-Kestose as a Candidate Precision Bioactive Component: From GH32-Dependent Gut Microbiota Regulation to Human Health Enhancement |
| Inulin Gut Randomized Trial | These observations provide a general rationale for testing whether co-administration of 1-kestose and long-chain inulin can influence colonic substrate availability and tolerability; the available experimental evidence is discussed in. | 3 | Fujii Tadashi (2026) | 1-Kestose as a Candidate Precision Bioactive Component: From GH32-Dependent Gut Microbiota Regulation to Human Health Enhancement |
| Inulin Gut Randomized Trial | Previous work showed that bacterial GH32 amino acid sequences can be grouped by phylogenetic analysis into clusters associated with distinct fructooligosaccharide-degrading profiles [].applies this framework to compare GH32 enzymes relevant to the utilization of 1-kestose and other fructans. | 3 | Fujii Tadashi (2026) | 1-Kestose as a Candidate Precision Bioactive Component: From GH32-Dependent Gut Microbiota Regulation to Human Health Enhancement |
| Inulin Gut Randomized Trial | 1 2 3 The gut microbiota is increasingly recognized as a key determinant of host physiology, and dysbiosis has been linked to a broad spectrum of diseases, including gastrointestinal, metabolic, immune, and neuropsychiatric disorders []. | 3 | Fujii Tadashi (2026) | 1-Kestose as a Candidate Precision Bioactive Component: From GH32-Dependent Gut Microbiota Regulation to Human Health Enhancement |
Source documents